ClinicalTrials.gg
Active, not recruitingNCT06442241Updated Mar 13, 2025

A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults

A Phase 1 interventional study of LYB005 low dose without adjuvant and LYB005 middle dose without adjuvant in Respiratory Syncytial Virus (RSV) and RSV Infection, sponsored by Guangzhou Patronus Biotech Co., Ltd.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Guangzhou Patronus Biotech Co., Ltd. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia — 1 open to participants now, 6 under way, 1 of them phase 3. Respiratory Syncytial Virus Infections · Australia.

Planned enrollment
30th of 44
84 · median 250
Started
2024
with 7 others
Phase 1
16 of 44
none open now
Registered
34th of 44
by date

Among the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, this one is the 30th largest by planned enrollment, is one of 8 that started in 2024, is one of 16 in phase 1, and was the 34th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 44 studies in Respiratory Syncytial Virus Infections with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Respiratory Syncytial Virus Infections with a site in Australia, or all of them as a file.
02

Study summary

A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.

Read the detailed description

The study design includes an age- and dose-escalation (low/middle/high dose) in two adult age groups (young adults [18-59 years] and older adults [≥60 years]). Study will be conducted in two parts, part 1 will enrolled young adults and part 2 will enroll older adults. A sentinel dosing approach will be used for close monitoring of safety to minimize risk to participants. Participants will be divided into the sentinel cohort and the remainder of cohort. Participants in part 1 will receive of one of two RSV vaccine formulations at one of 3 antigen dose levels or placebo. Participants in part 2 will receive of one of two RSV vaccine formulations at one of 3 antigen dose levels or positive control AREXVY. Detailed characterization of safety (including safety laboratory evaluation) and immune responses will be observed.

03

Conditions studied

  • Respiratory Syncytial Virus (RSV)
  • RSV Infection

Keywords

  • RSV vaccine
  • Virus Like Particle
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Part 1-A male or female aged 18-59 years at screening; Part 2-A male or female aged 60 years and older at screening.
  2. Written obtained from the subject before any assessment is performed.
  3. Subjects who the investigator believes that they can and will comply with the requirements of the protocol. (e.g., complete the diary cards, and complete follow-up visits).
  4. Subjects must have a (BMI) between ≥18.0 and ≤35.0 kg/m\^2 at screening.
  5. Female subjects who are not pregnant or lactating. Female subjects with and their partners should use highly effective, medically accepted double-barrier and will not have pregnancy and fertility plan and refrain from donating ovum from at least 28 days prior to study vaccination until study completion.

    • A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
    • Highly effective double-barrier contraception is defined as use of a condom AND one of the following: birth control pills (The Pill), depot or injectable birth control, intrauterine device (IUD), NuvaRing®, implantable contraception (e.g., Implanon).
    • Note: There is no contraception requirement for female subjects with non-childbearing potential (WNCBP). There is no contraception requirement for female subjects with non-childbearing potential (WNCBP) and WNCBP subjects' male partners must use a condom from study vaccination/Day 1 until study completion.
  6. Males participating in this study who are involved in heterosexual sexual activity with a female partner of childbearing potential must agree to use highly effective, medically accepted double-barrier contraception (as described above) and refrain from donating sperm from at least 28 days prior to study vaccination until study completion; male participants with WNCBP partners must use a condom only from study vaccination/Day 1 until study completion.

Exclusion criteria

Exclusion Criteria:

  1. Tympanic temperature > 37.5°C at screening or prior to vaccination.
  2. History or presence of any respiratory infection symptoms within 7 days prior to vaccination.
  3. Previous vaccination against Respiratory Syncytial Virus (RSV). Planned administration of RSV vaccination during the study (including an or non-registered vaccine), except for the investigational vaccine in this trial.
  4. Received a within 28 days before vaccination or received other vaccines within 14 days before vaccination.
  5. Received any immunoglobulins or blood/plasma products within 3 months prior to vaccination.
  6. Individuals with the following diseases: 1)Any acute disease or acute attack of chronic diseases or using antipyretic, analgesic or anti-allergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 24 h prior to enrolment; 2)Allergies to any component of the investigational vaccine; 3)Subject has any history of allergic conditions to other vaccines; 4)History of neurological disorders (convulsions, epilepsy, encephalopathy, etc.) or psychiatric disorders (bipolar disorder, schizophrenia, etc.) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study; 5)Asplenia, or functional asplenia; 6)Congenital or acquired immunodeficiency or disease; 7)Chronic administration (≥14 consecutive days) of (reference value for dose: ≥20 mg/day prednisone or equivalent) or other agents within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\<14 consecutive days) of oral corticosteroids; 8)Have severe cardiovascular diseases (cardiopulmonary disease, pulmonary edema), severe hepatic or renal diseases, and diabetes complications that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study; 9)History of severe thrombocytopenia or other coagulation disorders which may be for an IM; 10)Severe hypertension uncontrolled by medication with systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg; 11)Positive test for virus (HCV), surface antigen (HbsAg), (HIV) at screening.
  7. Clinically significant laboratory abnormalities determined by the investigator at screening.
  8. A positive urine drug test or alcohol breath test at screening or Day 1.
  9. Recent participated in another clinical trial, with receipt of the investigational drug/vaccine within 30 days prior to screening. Currently participating in or those planning to participate in another clinical trial during the study.
  10. Have donated blood or plasma within 2 weeks prior to screening.
  11. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Group 1 (LYB005 low dose without adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of low dose LYB005 (30μg) without adjuvant on Day 1.

    Biological: LYB005 low dose without adjuvant

  • Experimental
    Group 2 (LYB005 middle dose without adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of middle dose LYB005 (60μg) without adjuvant on Day 1.

    Biological: LYB005 middle dose without adjuvant

  • Experimental
    Group 3 (LYB005 high dose without adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of high dose LYB005 (120μg) without adjuvant on Day 1.

    Biological: LYB005 high dose without adjuvant

  • Experimental
    Group 4 (LYB005 low dose with adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of low dose LYB005 (30μg) with adjuvant on Day 1.

    Biological: LYB005 low dose with adjuvant

  • Experimental
    Group 5 (LYB005 middle dose with adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of middle dose LYB005 (60μg) with adjuvant on Day 1.

    Biological: LYB005 middle dose with adjuvant

  • Experimental
    Group 6 (LYB005 high dose with adjuvant; young adults)

    Young adults (18-59 years old) will receive a single injection of high dose LYB005 (120μg) with adjuvant on Day 1.

    Biological: LYB005 high dose with adjuvant

  • Placebo comparator
    Group 7 (placebo; young adults)

    Young adults (18-59 years old) will receive a single injection of placebo on Day 1.

    Biological: Placebo

  • Experimental
    Group 8 (LYB005 low dose without adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of low dose LYB005 (30μg) without adjuvant on Day 1.

    Biological: LYB005 low dose without adjuvant

  • Experimental
    Group 9 (LYB005 middle dose without adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of middle dose LYB005 (60μg) without adjuvant on Day 1.

    Biological: LYB005 middle dose without adjuvant

  • Experimental
    Group 10 (LYB005 high dose without adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of high dose LYB005 (120μg) without adjuvant on Day 1.

    Biological: LYB005 high dose without adjuvant

  • Experimental
    Group 11 (LYB005 low dose with adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of low dose LYB005 (30μg) with adjuvant on Day 1.

    Biological: LYB005 low dose with adjuvant

  • Experimental
    Group 12 (LYB005 middle dose with adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of middle dose LYB005 (60μg) with adjuvant on Day 1.

    Biological: LYB005 middle dose with adjuvant

  • Experimental
    Group 13 (LYB005 high dose with adjuvant; older adults)

    Older adults (≥60 years old) will receive a single injection of high dose LYB005 (120μg) with adjuvant on Day 1.

    Biological: LYB005 high dose with adjuvant

  • Active comparator
    Group 14 (AREXVY; older adults)

    Older adults (≥60 years old) will receive a single injection of positive control AREXVY on Day 1.

    Biological: Positive control

Interventions

  • BiologicalLYB005 low dose without adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalLYB005 middle dose without adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalLYB005 high dose without adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalLYB005 low dose with adjuvant

    Drug page: Adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalLYB005 middle dose with adjuvant

    Drug page: Adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalLYB005 high dose with adjuvant

    Drug page: Adjuvant

    Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalPlacebo

    0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

  • BiologicalPositive control

    AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Immediate AEs for 30 minutes post-vaccination

    The incidence and severity of any adverse events (AEs) within 30 minutes after the vaccination

    Time frame: 30 mins after vaccination

  2. Solicited local and systemic AEs and unsolicited AEs

    The incidence and severity of any solicited local and systemic AEs and unsolicited AEs within 7 days after the vaccination

    Time frame: Within 7 days after vaccination

  3. Unsolicited AEs

    The incidence and severity of any unsolicited AEs within 28 days after the vaccination

    Time frame: Within 28 days after vaccination

  4. Clinically significant laboratory abnormalities

    The occurrence of clinically significant laboratory abnormalities 3 days, 7 days, 28 days and 90 days after vaccination

    Time frame: Day 4, Day 8, Day 29 and Day 91

  5. Serious adverse events (SAEs) and adverse events of special interest (AESIs)

    The incidence of any serious adverse events (SAEs) and adverse events of special interest (AESIs) within 6 months after the vaccination

    Time frame: Within 6 months after the vaccination

Secondary outcomes

  1. To observe the humoral immunity (antibodies level) of LYB005 vaccine

    The geometric mean titer (GMT) of RSV A and RSV B neutralizing antibodies at 14 days and 28 days after the vaccination; the geometric mean concentration (GMC) of RSV PreF antibodies at 14 days and 28 days after the vaccination.

    Time frame: Day 15 and Day 29

  2. To observe the persistence of humoral immunity (antibodies level) of LYB005 vaccine

    The GMT of RSV A and RSV B neutralizing antibodies at 3 and 6 months after the vaccination; the GMC of RSV PreF antibodies at 3 and 6 months after the vaccination

    Time frame: Day 91 and Day 181

  3. To observe the humoral immunity (increase in antibodies level) of LYB005 vaccine

    The geometric mean fold rise (GMFR) of RSV A and RSV B neutralizing antibodies at 14 days and 28 days after the vaccination; the GMFR of RSV PreF antibodies at 14 days and 28 days after the vaccination.

    Time frame: Day 15 and Day 29

  4. To observe the persistence of humoral immunity (increase in antibodies level) of LYB005 vaccine

    The GMFR of RSV A and RSV B neutralizing antibodies at 3 and 6 months after the vaccination; the GMFR of RSV PreF antibodies at 3 and 6 months after the vaccination

    Time frame: Day 91 and Day 181

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2025, 16 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 16 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 4, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06442241
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Collaborators
Yantai Patronus Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Jul 31, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Mar 13, 2025

Study contacts

Christina Chang, M.D
principal investigator · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adjuvant

Start the discussion